Literature DB >> 9161927

Diagnosis of dementia in individuals with intellectual disability.

E H Aylward1, D B Burt, L U Thorpe, F Lai, A Dalton.   

Abstract

The foremost impediment to progress in the understanding and treatment of dementia in adults with intellectual disability is the lack of standardized criteria and diagnostic procedures. Standardized criteria for the diagnosis of dementia in individuals with intellectual disability are proposed, and their application is discussed. In addition, procedures for determining whether or not criteria are met in individual cases are outlined. It is the intention of the authors, who were participants of an International Colloquium on Alzheimer Disease and Mental Retardation, that these criteria be appropriate for use by both clinicians and researchers. Their use will improve communication among clinicians and researchers, and will allow researchers to test hypotheses concerning discrepancies in findings among research groups (e.g. dementia prevalence ranges and age of onset).

Entities:  

Mesh:

Year:  1997        PMID: 9161927     DOI: 10.1111/j.1365-2788.1997.tb00692.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  44 in total

1.  Mild cognitive impairment identified in older individuals with Down syndrome by reduced telomere signal numbers and shorter telomeres measured in microns.

Authors:  Edmund C Jenkins; Lingling Ye; Milen Velinov; Sharon J Krinsky-McHale; Warren B Zigman; Nicole Schupf; Wayne P Silverman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-16       Impact factor: 3.568

2.  Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

Authors:  R J Haier; K Head; E Head; I T Lott
Journal:  Neuroimage       Date:  2007-10-12       Impact factor: 6.556

3.  Estrogen receptor-alpha variants increase risk of Alzheimer's disease in women with Down syndrome.

Authors:  Nicole Schupf; Joseph H Lee; Michelle Wei; Deborah Pang; Constance Chace; Rong Cheng; Warren B Zigman; Benjamin Tycko; Wayne Silverman
Journal:  Dement Geriatr Cogn Disord       Date:  2008-04-14       Impact factor: 2.959

4.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

5.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

6.  Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status.

Authors:  D M Walsh; E Doran; W Silverman; A Tournay; N Movsesyan; I T Lott
Journal:  J Intellect Disabil Res       Date:  2015-05-29

7.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

8.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

9.  Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome.

Authors:  Joseph H Lee; Maruit Chulikavit; Deborah Pang; Warren B Zigman; Wayne Silverman; Nicole Schupf
Journal:  Neurosci Lett       Date:  2007-08-25       Impact factor: 3.046

10.  Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrations.

Authors:  A M W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; C M van Duijn
Journal:  Amino Acids       Date:  2009-05-20       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.